Allogene Therapeutics, Inc. business relationships

Companies named in Allogene Therapeutics, Inc.’s 10-K filed 2026-03-12, and public companies whose annual reports name Allogene Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.

Open on the map Full AI visibility profile

AEO visibility: 5.4 / 10
AI naming: 72 / 100
Agent readiness: 25 / 100
AI adoption: 0 / 100

Named in Allogene Therapeutics, Inc.’s annual report 7

BRISTOL MYERS SQUIBB CO (BMY)Sales channel7.7
“Autologous T cell therapies directed at CD19 have been commercialized by Novartis, Kite/Gilead and Bristol-Myers Squibb Company (BMS) and are witnessing increased adoption in the marketplace.” SEC filing
GILEAD SCIENCES, INC. (GILD)Sales channel7.7
“Autologous T cell therapies directed at CD19 have been commercialized by Novartis, Kite/Gilead and Bristol-Myers Squibb Company (BMS) and are witnessing increased adoption in the marketplace.” SEC filing
NOVARTIS AG (NVS)Sales channel7.7
“Autologous T cell therapies directed at CD19 have been commercialized by Novartis, Kite/Gilead and Bristol-Myers Squibb Company (BMS) and are witnessing increased adoption in the marketplace.” SEC filing
PFIZER INC (PFE)Licensee7.7
“Following the execution of the Pfizer Agreement, we are the owner of, co-owner of, or the licensee of multiple patents and patent applications in the United States and worldwide.” SEC filing
PFIZER INC (PFE)Licensor7.7
“...rograms, our patent rights are generally composed of patents and pending patent applications that are solely owned by us, co-owned with Servier, co-owned with Cellectis, co-owned with Pfizer, exclusively licensed from Pfizer, exclusively licensed from Servier, or exclusively licensed from Cellectis.” SEC filing
PFIZER INC (PFE)Partner7.7
“Collaboration Agreement by and between Servier and Pfizer, dated October 30, 2016, which Pfizer assigned to the Company in April 2018, will survive the termination of the Original Cellectis Agreement.” SEC filing
Cellectis S.A. (CLLS)Licensor5.4
“As part of the Pfizer Agreement, Pfizer assigned to the Company a Research Collaboration and License Agreement (the Original Cellectis Agreement) with Cellectis S.A. (Cellectis).” SEC filing

Companies whose annual reports name Allogene Therapeutics, Inc. 1

Cellectis S.A. (CLLS)names it as licensor5.4
“our receipt of milestone or royalty payments pursuant to our licensing agreements with Allogene Therapeutics, Inc. ("Allogene"), Les Laboratoires Servier and Institut de Recherches Internationales Servier (together "Servier") and AstraZeneca Ireland Limited ("AZ Ireland");” SEC filing

Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.